Jung Ah-Yeoun, Heo Min-Jeong, Kim Young Hyo
WCSL of INtegrated Human Airway-on-a-chip, Department of Otorhinolaryngology, Inha University, Incheon, Korea.
Int Forum Allergy Rhinol. 2017 Aug;7(8):763-769. doi: 10.1002/alr.21967. Epub 2017 May 30.
Glucosamine (GlcN) is generally used as a dietary supplement because of its antiinflammatory effects. We evaluated the antiallergic effect of GlcN in mice with allergic asthma and rhinitis.
Thirty-two mice were allocated equally into 4 groups (n = 8). In group A (control), we performed intraperitoneal/intranasal challenge using sterile saline. In group B (asthma/rhinitis), we used ovalbumin for intraperitoneal/intranasal challenge to induce allergic asthma and rhinitis. In groups C and D (GlcN treatment), mice were given 1% and 5% GlcN throughout the period of ovalbumin challenge, respectively. We measured serum total and ovalbumin-specific immunoglobulin E (IgE), cytokine titers (interleukin-1, -4, -5, -6, -10, and -17; tumor necrosis factor-α; and interferon-γ), and the number of inflammatory cells (eosinophils, neutrophils, lymphocytes) in bronchoalveolar lavage (BAL) fluid. We also performed histopathologic examination of the lung and nasal cavity. Finally, we performed real-time polymerase chain reaction for the genes Bcl-2, EC-SOD, VEGF, caspase-3, Bax, COX-2, Hif-1α, and heme oxygenase-1.
Compared with group B, group D had significant serum total and ovalbumin-specific IgE decreases after GlcN treatment (p < 0.05). Titers for IL-4, IL-5, IL-6, and IL-17 in BAL fluid were significantly decreased in group D (p < 0.05). Eosinophils in BAL fluid were significantly decreased in group D compared with group B (p < 0.05). Groups C and D showed significant improvement of inflammation compared with group B. Group D had significant downregulation of EC-SOD, Bax, Hif-1α, and heme oxygenase-1 compared with group B.
GlcN had a significant antiallergic effect in mice with allergic asthma and rhinitis.
氨基葡萄糖（GlcN）因其抗炎作用通常用作膳食补充剂。我们评估了GlcN对过敏性哮喘和鼻炎小鼠的抗过敏作用。
32只小鼠平均分为4组（n = 8）。A组（对照组）使用无菌盐水进行腹腔/鼻内激发。B组（哮喘/鼻炎组）使用卵清蛋白进行腹腔/鼻内激发以诱导过敏性哮喘和鼻炎。C组和D组（GlcN治疗组）在卵清蛋白激发期间分别给予1%和5%的GlcN。我们测量了血清总免疫球蛋白E和卵清蛋白特异性免疫球蛋白E（IgE）、细胞因子滴度（白细胞介素-1、-4、-5、-6、-10和-17；肿瘤坏死因子-α；以及干扰素-γ），以及支气管肺泡灌洗（BAL）液中炎症细胞（嗜酸性粒细胞、中性粒细胞、淋巴细胞）的数量。我们还对肺和鼻腔进行了组织病理学检查。最后，我们对Bcl-2、细胞外超氧化物歧化酶（EC-SOD）、血管内皮生长因子（VEGF）、半胱天冬酶-3、Bax、环氧合酶-2（COX-2）、低氧诱导因子-1α（Hif-1α）和血红素加氧酶-1基因进行了实时聚合酶链反应。
与B组相比，D组在GlcN治疗后血清总IgE和卵清蛋白特异性IgE显著降低（p < 0.05）。D组BAL液中白细胞介素-4、白细胞介素-5、白细胞介素-6和白细胞介素-17的滴度显著降低（p < 0.05）。与B组相比，D组BAL液中的嗜酸性粒细胞显著减少（p < 0.05）。与B组相比，C组和D组的炎症有显著改善。与B组相比，D组的EC-SOD、Bax、Hif-1α和血红素加氧酶-1有显著下调。
GlcN对过敏性哮喘和鼻炎小鼠有显著的抗过敏作用。
